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Abstract Results
Conclusion
Ureteral cancer is extremely rare, with only 3530 cases 
predicted in 2016.  Therefore, published studies on ureteral 
cancers are limited to single-institution retrospective 
studies, which have not elucidated a clear recommendation 
on the best treatment modality.  Large cancer databases 
such as the Surveillance, Epidemiology, and End Results 
program (SEER) are ideal for providing data for these rare 
cancers. Epidemiological studies using the SEER database 
with large sample sizes (13,800) found rising incidence of 
ureteral cancer over the past 30 years with worsened 
outcomes in older patients, males, and patients with 
regional/distant spread. However, to date, these studies 
have not used the available data in the SEER databases to 
stratify survival outcomes based on different treatment 
modalities. The purpose of this study is to assess the 
overall survival (OSS), cause-specific survival (CSS) and 
effect of intervention (surgery and postoperative 
radiotherapy) in patients with ureteral carcinoma.
Methods
References
The Surveillance, Epidemiology, and End Results (SEER) 
database is a national cancer database run by the National 
Cancer Institute that records all incident cases from 18 
registries covering 28% of the US population. The SEER 
registries collect data on patient demographics, primary 
tumor site, disease extent, course of treatment and follow 
up.  Data is de-identified and available for public use.  Using 
the SEER database, we identified patients with 
pathologically confirmed primary tumor of renal pelvis and 
ureters using International Classification of Diseases codes 
ICD-O-3 codes 65.9 (renal pelvis) and 66.9 (ureter) who 
underwent attempted curative surgery for their diagnosis 
between 1995 and 2012.  Exclusion criteria included in-situ 
disease, metastatic disease, preoperative radiotherapy, 
brachytherapy, or patients with incomplete information 
regarding tumor staging, treatment or outcomes. Localized 
disease was defined as “confined to the organ of origin 
without extension beyond the primary organ” while a tumor 
with regional extension were those with “direct extension to 
adjacent organs or structures or spread to regional lymph 
nodes” As a result of this inclusion criteria, a total of 6,057 
patients were included for analysis. Categorical variables 
included histology, patient age at diagnosis, gender, race, 
year of diagnosis, primary site (renal pelvis vs. ureter), 
extent of disease (localized vs. regional), and use of 
adjuvant RT. Cause specific survival (CSS) was the primary 
endpoint. This was determined using specified cause of 
death from either ureteral or renal pelvis carcinoma and 
was measured from date of diagnosis until death. Overall 
survival (OS) was measured from the date of diagnosis to 
the date of death from any cause. Kaplan-Meier plot and 
Wilcoxon test were used to evaluate survival of patients in 
regards to radiation. In the next step, patients then stratified 
based on the stage to evaluate effects of adjuvant 
radiotherapy in each stage.
6057 patients were identified with a mean age of 
70.57±10.37SD, 64.88% were male, 61.32% had renal pelvic 
carcinoma and 38.68% had ureteral carcinoma, 2601 (42.94%) 
had localized tumor and 3456 (57.06%) had regional disease. 
The majority of cases were transitional cell carcinoma (96.67%), 
all patients underwent surgery and 217 (3.58%) received 
adjuvant RT. For the 5840 patients who only received curative 
surgery, 64.81% were male, 61.83% had renal pelvic carcinoma 
and 38.17% had ureteral carcinoma, 3611 (61.83%) had 
localized tumor and 2229 (38.17%) had regional disease. For the 
217 patients who received adjuvant radiotherapy in addition to 
curative surgery 66.82% were male, 47.46% had renal pelvic 
carcinoma and 52.53% had ureteral carcinoma, 22 (10.14%) had 
localized tumor and 195 (89.86%) had regional disease. (table 1) 
CSS at 1, 2 and 5 years was 98%, 94.6% and 86.1% without 
adjuvant RT and 92.1%, 84.7% and 69.4% with adjuvant RT 
(p<0.0001) (figure1). 
Given the large variation in disease stage between the subgroup 
of patients who received adjuvant RT and those who did not , we 
also analyzed survival stratified by disease stage. CSS for local 
disease at 1, 2 and 5 years was 98.8%, 97.5% and 91.5% 
without adjuvant RT and 90.7%, 85.3% and 85.3% with adjuvant 
RT. CSS for regional disease at 1, 2 and 5 years was 97.3%, 
92% and 80.7% without adjuvant RT and 92.3%, 84.5% and 
66.9% with adjuvant RT. (figures 2 and 3)
On multivariate analysis, older age, regional extension, and 
postoperative RT had a negative impact on both overall survival 
and cause-specific survival. Specifically, receiving postoperative 
RT had a hazard ratio of 2.16 with Confidence Interval of 1.63 to 
2.85. Female sex was associated positively with OS but 
negatively with CSS. (table 2)
This is a large population-based study to look at the role of 
adjuvant RT in patients with ureteral carcinoma. In this 
nonrandomized population, adjuvant RT was used in a 
minority of patients and showed a detriment in both OS and 
CSS. After stratifying based on stage, adjuvant RT was still 
associated with decreased OS and CSS in both localized and 
regional disease. However, it is likely that post-op RT was 
used in cases where there were pathologic risk features 
showing high risks for recurrence, such as R1/R2 resections, 
larger tumors, lymph node positive disease, etc. Further 
elucidation of risk features and the role of RT in this rare 
disease warrant more investigation.  
n (%)
Mean ± SD
Total patients
n=6057
Curative 
surgery
n=5840 
(96.42%)
Curative surgery + 
adjuvant 
radiotherapy
n=217 (3.58%)
Sex
Male
Female
3930 (64.88%)
2127 (35.12%)
3785 (64.81%)
2055 (35.19%)
145 (66.82%)
72 (33.18%)
Race
Caucasian
African-American
Others
Unknown
5508 (90.94%)
209 (3.45%)
337 (5.56%)
3 (0.05%)
5313 (90.98%)
201 (3.44%)
323 (5.53%)
3 (0.05%)
195 (89.86%)
8 (3.69%)
14 (6.45%)
0 (0%)
Primary tumor site
Renal pelvis
Ureter
3714 (61.32%)
2343 (38.68%)
3611 (61.83%)
2229 (38.17%)
103 (47.46%)
114 (52.53%)
Tumor stage
Local
Regional
2601 (42.94$%)
3456 (57.06%)
3611 (61.83%)
2229 (38.17%)
22 (10.14%)
195 (89.86%)
Histology
Transitional cell carcinoma
Squamous cell neoplasms
Epithelial neoplasms, not 
otherwise specified
Adenocarcinoma
Others
5855 (96.67%)
89 (1.47%)
31 (0.51%)
61 (1.01%)
21 (0.35%)
5651 (96.76%)
82 (1.4%)
28 (0.48%)
58 (0.99%)
21 (0.36%)
204 (94.01%)
7 (3.23%)
3 (1.38%)
3 (1.38%)
0 (0%)
Table 1: Predictors of surgical and adjuvant radiotherapy usage in ureteral 
cancer
Figure 1: Kaplan-Meier plot of cause-specific survival stratified for all patients by 
adjuvant radiotherapy use. Blue line represents patients who only underwent 
surgery, red line represents patients who underwent surgery and radiotherapy
Figure 2: Kaplan-Meier plot of cause-specific survival for patients with localized 
disease stratified by adjuvant radiotherapy use. Blue line represents patients who 
only underwent surgery, red line represents patients who underwent surgery and 
radiotherapy
Figure 3: Kaplan-Meier plot of survival for patients with regional disease stratified 
by adjuvant radiotherapy use. Blue line represents patients who only underwent 
surgery, red line represents patients who underwent surgery and radiotherapy
Overall Survival Cause-Specific Survival
Hazard 
Ratio
95% Hazard Ratio 
Confidence Limits
Hazard 
Ratio
95% Hazard Ratio 
Confidence Limits
Radiation:
Yes
1.433 1.233 1.665 2.159 1.634 2.852
Gender:
Female
0.877 0.823 0.935 1.200 1.044 1.378
Stage:
Regional
1.529 1.436 1.627 2.020 1.746 2.338
Primary 
site:
Renal 
Pelvis
0.977 0.918 1.040 1.202 1.041 1.388
Table 2: Multivariate analysis comparison of overall and cause-specific survival 
by prognostic factor
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